First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.
We aimed to explore the use of platinum plus bevacizumab in a real world NSCLC population. We retrospectively collected data from patients affected by NS-NSCLC treated with platinum plus bevacizumab across Tuscany. We evaluated 62 (median age: 63.5 [30-77] years) pts. All but one presented with adenocarcinoma and the majority had ECOG PS of 0/1. 17.7% presented with central lesion, 11.3% with brain metastasis, 38.7% with hypertension and 4.8% with mild haemoptysis. We observed a median time to progression (TTP) of 6.5 [2-37] and a median overall survival (OS) of 10.5 [2-39] months. Overall response rate (ORR) was 59.6% with a disease control rate (DCR) of 80.6%. Safety profile was acceptable. We observed five cardiovascular events and two major bleedings with no toxic deaths. Safety and efficacy real world data are consistent with those from clinical trials even in a less selected population.